Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
The Hippocratic Editorial and VT team. Please send your suggestions to [email protected]
Latest posts by Hippocratic Post (see all)
- Extreme heat in the UK – need for human-centred policies - September 3, 2026
- Oral-health videos to protect children with heart disease - September 3, 2026
- Dual drug therapy for Parkinson’s - September 3, 2026
